The concept of Foxp3+ regulatory T (Treg) cell-based therapies to interfere with β cell autoimmunity in T1D has been fueled in large part by evidence indicating that diminished Treg cell activity may contribute to disease pathogenesis. Here, FOXP3 is linked to type 1 diabetes mellitus.